492
Participants
Start Date
October 29, 2018
Primary Completion Date
July 12, 2022
Study Completion Date
July 12, 2022
AZD3759
AZD3759 200mg PO BID.
Erlotinib
SoC EGFRTKI Erlotinib 150 mg PO Q.D
Gefitinib
SoC EGFRTKI Gefitinib 250 mg PO Q.D
Taiwan site, Taipei
Taiwan site, Taoyuan District
Taiwan site, Taichung
Taiwan site, Tainan City
Korea site, Gyeonggi-do
Korea site, Suwon
Korea site, Incheon
Korea Site, Jungbuk
Korea site, Daegu
Korea site, Ulsan
Korea site, Gyeongsang
China site, Beijing
China site, Beijing
China site, Beijing
China site, Beijing
China site, Changchun
China site, Changchun
China site, Haerbin
China site, Shanghai
China site, Shanghai
China site, Nanjing
China site, Nanjing
China site, Wuxi
China site, Suzhou
China site, Xuzhou
China site, Yangzhou
China site, Hefei
China site 0123, Jinan
China site, Weifang
China site, Yantai
China site, Linyi
China site, Tianjin
Singapore site, Singapore
China site, Hangzhou
China site, Hangzhou
China site, Hangzhou
China site, Fuzhou
China site, Xiamen
China site, Chongqing
China site, Chongqing
China site, Chongqing
China site, Changsha
China site, Wuhan
China site, Wuhan
China site, Wuhan
China site, Yichang
China site, Zhengzhou
China site, Zhengzhou
China site, Guangzhou
China site, Guangzhou
China site, Chengdu
China site, Kunming
China site, Xi'an
Korea Site, Seoul
Korea site, Seoul
Korea Site, Seoul
Korea site, Seoul
Korea site, Seoul
Alpha Biopharma (Jiangsu) Co., Ltd.
INDUSTRY